BIOCORP
27.9.2021 06:47:07 CEST | Business Wire | Press release
Regulatory News:
BIOCORP (Paris:ALCOR) (FR0012788065 – ALCOR / Eligible PEA PME), a French company specialized in the design, development, and manufacturing of innovative medical devices, today announces an agreement with Novo Nordisk, a world leader in diabetes care, for the development and distribution (pending successful development) of a Mallya smart add-on device for the Novo Nordisk FlexTouch pen used by people with diabetes.
Mallya is a Bluetooth enabled smart add-on device for pen injectors that collects dose and time of each injection and transfers information in real time to a companion software. Mallya helps people with diabetes maintain a reliable dose log, using technology to help improve understanding and allowing people to dose with confidence.
Most Novo Nordisk's insulins are offered with the FlexTouch pen, and it is part of the launch map for all new insulins. A specific version of Mallya will be developed for FlexTouch, the first prefilled insulin delivery device with no-push-button extension. Due to the unique dosing mechanism of FlexTouch, the push button does not extend at any dose and allows insulin to be administered by pressing the low injection force button. The existing Mallya device had to be redesigned to meet the needs of this mechanism, keeping its accuracy and reliability for the patient.
Directly attached on the disposable pre-filled FlexTouch pen, Mallya will allow seamless and efficient dose logging on FlexTouch, which could help people with diabetes and their HCPs to have more personalized conversations about the disease and treatment compliance.
Biocorp will receive an upfront payment and different milestones are defined staging the development phase. Upon successful development, Novo Nordisk plans to distribute the smart device in selected countries, and Biocorp expects to ramp up production volumes from 2022. Financials and terms of contract are not disclosed.
“Novo Nordisk collaborates with Biocorp as we believe people with diabetes deserve the freedom to decide which solution works best for them. Our Swedish study1 demonstrates the health benefits associated with the use of smart insulin pens. And as we continue launching such smart pens, we also partner with Biocorp to allow even more people with diabetes to reap the benefits connected devices can provide. This collaboration demonstrates our commitment to making diabetes management easier by giving people access to data on medication usage behaviour which is known to potentially result in improved patient outcomes”, said Søren Smed Østergaard, vice president of Digital Health at Novo Nordisk.
“Biocorp is very proud to sign this partnership with the world's leading diabetes company, Novo Nordisk, and it is a huge recognition for our Mallya. Providing almost 50% of the insulin used worldwide, Novo Nordisk distributed more than 500 million insulin pens in 2020, treating close to 30 million patients. The FlexTouch pen is not concerned by Mallya's current version, while used by tens of millions of patients with diabetes in the world, so we are pleased to be working to open up the possibilities of connectivity for the many patients around the world who use this pen. ”, said Éric Dessertenne, CEO of BIOCORP.
ABOUT BIOCORP
Recognized for its expertise in the development and manufacture of medical devices and delivery systems, BIOCORP has today acquired a leading position in the connected medical device market thanks to Mallya. This smart sensor for insulin injection pens allows reliable monitoring of injected doses and thus offers better compliance in the treatment of patients with diabetes. Available for sale from 2020, Mallya spearheads BIOCORP's product portfolio of innovative connected solutions. The company has 70 employees. BIOCORP is listed on Euronext since July 2015 (FR0012788065 – ALCOR).
For more information, please visit www.biocorpsys.com .
1 “Increased Time in Range and Fewer Missed Bolus Injections After Introduction of a Smart Connected Insulin Pen ”, Diabetes Technology & Therapeutics, Vol: 22(7), 2020.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210926005031/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Instabase Becomes SuperApp, Launches the AI Collaboration Super App17.8.2026 12:00:00 CEST | Press release
AI was single-player. SuperApp makes it multiplayer Your whole team and leading AI models from Anthropic, OpenAI, Google, xAI, and others think, debate, and create together in one live thread — from the first idea to the final deliverable. Available today. SuperApp, Inc., formerly Instabase, Inc., today launched SuperApp, the AI collaboration super app, available on the web, iOS, Android, and desktop. SuperApp brings teams and leading AI models from Anthropic, OpenAI, Google, xAI, and others into one live thread — from the first conversation to finished work. The company changed its name to reflect the new product and company direction. Work today is split into three. Teams talk in one app. They ask AI in another. They make the final work somewhere else. Every handoff asks people to remember what the software forgot. SuperApp brings those moments together. People and AI begin in the same live thread. Teams can use Claude from Anthropic, GPT from OpenAI, Gemini from Google, Grok from xA
Confluence Launches Confluence POINT, Bringing AI-Enabled Automation Across Its Product Suite.17.8.2026 11:04:00 CEST | Press release
Document validation and intelligence and the Revolution conversational interface are live today; the first in a wave of AI capabilities running within and alongside Confluence’s solutions. Confluence Technologies, Inc. (“Confluence”), a global leader in regulatory, analytics, and investor communications solutions for the investment management industry, today announced the launch of Confluence POINT, AI-enabled automation that optimizes workflows across its solutions. Confluence delivers specialist regulatory, analytics and investor solutions that are unrivalled at what they do. POINT is AI-enabled automation that runs within and alongside these solutions, letting them do more for our clients, reducing manual effort that typically occurs before or after automated processes. POINT Validation transforms and validates documents across a range of formats, including unstructured data. POINT’s AI-powered validation is complete in minutes, delivered via an automated checklist that runs indepen
Xsolla Adds 15+ New Local Payment Methods, Letting Game Developers Reach Players Across Asia-Pacific, Europe, and the Americas17.8.2026 10:00:00 CEST | Press release
Now Live: Mandiri, ShopeePay, LINE Pay, Octopus, Konbini 7/11, China UnionPay, Zip Co, Wero, Pay by Bank, FLOA Pay BNPL, Bancomat Pay, MyBank, IRIS Commerce, CliQ, and Aeropay Xsolla, a global video game commerce company, today announced the addition of 15+ new payment methods to Xsolla Payments ahead of Gamescom 2026, spanning Asia and Oceania, EMEA, and the Americas. Game developers and publishers can now accept the local payment methods players already use, across markets from Indonesia and the Philippines to Germany, France, and the United States, with no additional integration required for any individual method. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260817000143/en/ Graphic: Xsolla The shift toward local payment methods is reshaping the digital payments landscape well beyond emerging markets. Across Europe, banks and regulators are building account-to-account and instant-payment alternatives to international ca
SES Expands into Global Direct-to-Device Services through Strategic Collaboration with Elveo Mobile17.8.2026 09:30:00 CEST | Press release
SES, a global leader in space solutions, today announced an expanded strategic investment and collaboration with Elveo Mobile (Elveo), the new company created through the completion of the Lynk and Omnispace merger. Elveo unites the heritage of two pioneers in direct-to-device (D2D) services and will deliver mobile connectivity from space to mobile phones, devices and machines around the world. SES will support Elveo in accelerating its delivery of powerful, cost-effective global D2D services. SES and Elveo will also work together on global spectrum initiatives that will enable Elveo to unlock delivery of D2D solutions. By partnering with Elveo, SES deepens its commitment with access to its expansive, global space and ground infrastructure, while also supporting Elveo's go-to-market, engineering, operations and regulatory needs. The collaboration will enable SES to enhance current services for its mobile telecom, enterprise, and government customers around the world. SES users will ben
Trading Central Launches a UCITS ETF17.8.2026 09:30:00 CEST | Press release
Trading Central SA (“Trading Central”) announces the launch of a UCITS European Quant ETF in partnership with HANetf Asset Management, one of Europe’s leading white-label UCITS ETF and ETC platforms. The following ETF is now trading on Euronext Paris (eligible to PEA), Milan, Dublin, and Börse Frankfurt, and is coming soon to more European stock exchanges and in currencies besides the Euro. Trading Central Quant Europe 50 Equity UCITS ETF (TCQE) J.P. Morgan serves as fund administrator and custodian, while GTX acts as the market maker across these exchanges. This release marks Trading Central’s continued expansion into investable products, supporting self-directed retail clients with its award-winning, proprietary financial research and data. “For years, Trading Central has helped investors make more informed decisions through independent research and analytics,” said Alain Pellier, CEO of Trading Central SA. “The introduction of our TC Quant ETF is a natural next step in our mission—o
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom